Back to top
more

Accuray (ARAY)

(Delayed Data from NSDQ)

$2.03 USD

2.03
1,391,366

+0.11 (5.73%)

Updated Nov 6, 2024 04:00 PM ET

After-Market: $1.97 -0.06 (-2.96%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (63 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Accuray (ARAY) Is Up 1.82% in One Week: What You Should Know

by Zacks Equity Research

Does Accuray (ARAY) have what it takes to be a top stock pick for momentum investors? Let's find out.

Accuray (ARAY) Inks Cancer Treatment Technology Delivery Deal

by Zacks Equity Research

Accuray's (ARAY) new deal with DHL Supply Chain will help in the delivery of advanced cancer treatment technology.

Accuray (ARAY) Climbs 11.5% as Q1 Earnings Beat Estimates

by Zacks Equity Research

Accuray (ARAY) registered growth in Service revenues in Q1.

Accuray (ARAY) Reports Break-Even Earnings for Q1

by Zacks Equity Research

Accuray (ARAY) delivered earnings and revenue surprises of 100.00% and 10.82%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Will Accuray (ARAY) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Accuray (ARAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why You Should Retain Accuray (ARAY) Stock for Now

by Zacks Equity Research

Investors' confidence is high in the Accuray (ARAY) stock, thanks to its solid prospects.

The Zacks Analyst Blog Highlights: Medtronic, Boston Scientific, DaVita, Accuray and Cardinal Health

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Medtronic, Boston Scientific, DaVita, Accuray and Cardinal Health

Sriparna Ghosal headshot

3 Best MedTech Value Stocks to Buy Ahead of Q3 Earnings

by Sriparna Ghosal

These three MedTech stocks are expected to grow post their Q3 earnings release.

Idexx (IDXX) Hits 52-Week High, Can the Run Continue?

by Zacks Equity Research

Idexx (IDXX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Trina Mukherjee headshot

Robot-Assisted Surgery Gains Momentum Amid Coronavirus

by Trina Mukherjee

Let's keep a watch on potentially strong three MedTech stocks with respect to robotic-assisted surgery that have shown promise during the pandemic.

Accuray's Radixact With Synchrony Used in Japan Hospitals

by Zacks Equity Research

The integration of Synchrony to Accuray's (ARAY) Radixact System will ensure that the hospital teams can efficiently deliver precise radiation doses to tumors.

Accuray (ARAY) Down 16.5% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Accuray (ARAY) Reports Loss in Q4, Revenues Miss Estimates

by Zacks Equity Research

Accuray (ARAY) registered decline in Product and Service revenues in Q4

Accuray (ARAY) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Accuray (ARAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sriparna Ghosal headshot

3 Large-Cap MedTech Stocks to Buy on Northbound Market Trend

by Sriparna Ghosal

Backed by an upward trend of share prices and projections of robust earnings growth rates, there are a few MedTech stocks which are ideal for long-term bet.

Sriparna Ghosal headshot

Coronavirus Spurs Growth for 3 Robotics-Assisted Surgery Stocks

by Sriparna Ghosal

In the face of the pandemic, the robotics-assisted surgery space continues to thrive on a slew of positive developments.

Here's Why You Should Add Surmodics to Your Portfolio Now

by Zacks Equity Research

Investor confidence is high on Surmodics (SRDX), thanks to solid prospects.

Accuray's New CyberKnife S7 System to Boost Patient Care

by Zacks Equity Research

Accuray's (ARAY) newly launched CyberKnife S7 System will enable clinicians to provide best possible care to their patients through new capabilities.

Here's Why You Should Add Accuray to Your Portfolio Now

by Zacks Equity Research

Investor confidence is high on Accuray (ARAY) stock, thanks to solid prospects.

Why Is Accuray (ARAY) Down 9.2% Since Last Earnings Report?

by Zacks Equity Research

Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

6 Stocks to Benefit From the 'New Normal'

by Zacks Equity Research

The coronavirus-led 'new normal' has altered several businesses. Here are three sectors that will see a boom in the near future.

Delivery Robots Making an Impression Amid Coronavirus Pandemic

by Zacks Equity Research

Since the coronavirus outbreak, robots have filled up several job vacancies caused by social distancing orders. Here are five robotics and related stocks investors should closely watch.

How Accuray (ARAY) Stock Stands Out in a Strong Industry

by Zacks Equity Research

Accuray (ARAY) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Will Accuray (ARAY) Gain on Rising Earnings Estimates?

by Zacks Equity Research

Accuray (ARAY) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

What Makes Accuray (ARAY) a New Strong Buy Stock

by Zacks Equity Research

Accuray (ARAY) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.